Renexxion and Dr. Falk Pharma Begin U.S. Patient Dosing in Global Phase 2b Study for Promising Gastroparesis Treatment

Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high u...

August 14, 2024 | Wednesday | News
Shanghai Junshi Biosciences’ Toripalimab sNDA Accepted by NMPA for First-Line Treatment of Advanced Melanoma

Shanghai Junshi Biosciences Co., a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of ...

August 13, 2024 | Tuesday | News
Persist AI and Nivagen Announce Strategic Collaboration to Transform Long-Acting Injectable Drug Manufacturing

Persist AI and Nivagen have announced a collaboration to co-develop a next-generation manufacturing process for long-acting injectable (LAI) drugs, ...

August 13, 2024 | Tuesday | News
Merck to Acquire Curon Biopharmaceutical’s CN201, Expanding Pipeline in B-Cell Associated Diseases

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Curon Biopharmaceutical (Curon), a privately held biotechnology company, &nb...

August 12, 2024 | Monday | News
Novartis' Fabhalta® Receives FDA Accelerated Approval for IgA Nephropathy Treatment

Novartis is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta® (iptacopan), a ground...

August 08, 2024 | Thursday | News
Integrated DNA Technologies Launches Rapid Genes for Expedited Drug Discovery

To enable pharmaceutical researchers to move quickly into their high‑throughput screening experiments, global genomics solutions provider Integrated DNA ...

August 08, 2024 | Thursday | News
Daiichi Sankyo and MSD Expand Collaboration to Co-Develop and Co-Commercialize DLL3 T-Cell Engager MK-6070

Agreement builds on and complements Daiichi Sankyo and Merck’s shared commitment to develop novel medicines for patients with cancer Daiichi Sanky...

August 07, 2024 | Wednesday | News
Fifty 1 Labs and All-In-Extracts Announce Joint Venture for Innovative Testosterone-Boosting Supplement

Fifty 1 Labs, Inc. , a holding company that operates in the sports supplement, fitness equipment, and health and wellness industries, and All-In-Extracts...

August 06, 2024 | Tuesday | News
Molecure and Avicenna Biosciences Announce Strategic Collaboration to Develop Novel Cancer Therapies Targeting USP7

Molecure S.A. (‘Molecure’, SWE Ticker: MOC) and Avicenna Biosciences, Inc. announced today that they have entered into a strategic research c...

August 01, 2024 | Thursday | News
FDA Grants Priority Review to Vertex's Suzetrigine, Targeting January 2025 for Action Date

FDA grants priority review and assigns a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2025 – – Suzetrigine...

July 30, 2024 | Tuesday | News
Charles River Partners with Autobahn Labs to Accelerate Academic Drug Discovery and Development

Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to acceler...

July 25, 2024 | Thursday | News
Innovent Biologics Announces Phase 3 Success for Mazdutide in Treating Type 2 Diabetes

Innovent Biologics, a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of on...

July 22, 2024 | Monday | News
Teva Pharmaceuticals’ AJOVY Achieves Primary End Point in Pediatric Phase 3 Migraine Study

SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to ...

July 19, 2024 | Friday | News
Shanghai Junshi Biosciences' sNDA for Toripalimab and Bevacizumab Combo for Advanced Liver Cancer Accepted by NMPA

  Shanghai Junshi Biosciences Co., a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercializati...

July 19, 2024 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close